Gilead Sciences (GILD) Holding Has Boosted by Visionary Asset Management Inc; Johnson And Johnson (JNJ) Stock Declined While Alpine Partners Vi Lifted by $1.80 Million Its Position

May 18, 2018 - By Clifton Ray

Johnson & Johnson (NYSE:JNJ) Logo

Alpine Partners Vi Llc increased its stake in Johnson And Johnson (JNJ) by 415.65% based on its latest 2017Q4 regulatory filing with the SEC. Alpine Partners Vi Llc bought 12,985 shares as the company’s stock declined 9.21% with the market. The institutional investor held 16,109 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $2.25 million, up from 3,124 at the end of the previous reported quarter. Alpine Partners Vi Llc who had been investing in Johnson And Johnson for a number of months, seems to be bullish on the $331.65 billion market cap company. The stock decreased 0.16% or $0.2 during the last trading session, reaching $123.65. About 734,631 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since May 18, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.




Visionary Asset Management Inc increased its stake in Gilead Sciences Inc (GILD) by 1457.63% based on its latest 2017Q4 regulatory filing with the SEC. Visionary Asset Management Inc bought 39,356 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 42,056 shares of the health care company at the end of 2017Q4, valued at $3.01 million, up from 2,700 at the end of the previous reported quarter. Visionary Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $88.12B market cap company. The stock increased 0.25% or $0.17 during the last trading session, reaching $67.77. About 563,970 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 18, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Lipotoxicity And NASH: Gilead’s Actions Speak Louder Than Words” on May 09, 2018, also 247Wallst.com with their article: “Analysts Show More Caution Toward Gilead’s Mystical Recovery” published on May 02, 2018, Bizjournals.com published: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” on May 17, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “FDA OKs expanded use for Gilead’s Truvada” with publication date: May 15, 2018.

Visionary Asset Management Inc, which manages about $656.56 million and $359.13M US Long portfolio, decreased its stake in Ishares Tr (IEI) by 7,494 shares to 127,311 shares, valued at $15.55M in 2017Q4, according to the filing. It also reduced its holding in Valero Energy Corp New (NYSE:VLO) by 40,960 shares in the quarter, leaving it with 2,611 shares, and cut its stake in Ishares Tr (AGG).

Since January 2, 2018, it had 0 buys, and 22 selling transactions for $44.80 million activity. $2.37 million worth of stock was sold by Alton Gregg H on Thursday, January 11. MARTIN JOHN C had sold 50,000 shares worth $3.66M on Monday, April 2. $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Meyers James R. Washington Robin L sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 21. WILSON GAYLE E sold 60,000 shares worth $4.68 million.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. On Monday, September 12 the stock rating was initiated by Berenberg with “Buy”. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, July 29. RBC Capital Markets has “Outperform” rating and $130 target. The company was maintained on Friday, July 24 by Piper Jaffray. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Tuesday, October 25 by Jefferies. Bank of America upgraded it to “Neutral” rating and $107 target in Monday, January 18 report. The firm has “Neutral” rating given on Friday, December 18 by Atlantic Securities. The firm has “Buy” rating by Cowen & Co given on Monday, September 21. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, October 27 report. On Wednesday, October 4 the stock rating was initiated by Oppenheimer with “Hold”. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, January 2.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It dropped, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Cypress Cap Grp Inc accumulated 41,178 shares or 0.61% of the stock. Ameritas Investment Ptnrs Incorporated holds 64,551 shares or 0.21% of its portfolio. Sky Gp Ltd Liability Company has 16,407 shares. Oppenheimer Asset Mngmt Inc has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Regions Financial accumulated 72,355 shares. Greatmark Inv Prtnrs Incorporated has 2.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 77,304 shares. Aldebaran Fin Inc has 0.85% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Mutual Of Omaha State Bank Wealth Management reported 0.12% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Main Street Ltd Liability holds 0.08% or 7,367 shares. National Mutual Ins Federation Of Agricultural Cooperatives accumulated 24,500 shares. Ifrah Fin reported 5,484 shares or 0.14% of all its holdings. Raab Moskowitz Asset Mgmt Ltd Liability invested 0.44% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Neumann Mngmt Llc reported 50,770 shares. 48,409 are owned by Moneta Gru Advsr Limited Liability Company. Factory Mutual Ins invested in 0.44% or 588,900 shares.

Investors sentiment increased to 0.87 in 2017 Q4. Its up 0.04, from 0.83 in 2017Q3. It is positive, as 35 investors sold JNJ shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. Shelton Capital Management reported 0.33% in Johnson & Johnson (NYSE:JNJ). Sawgrass Asset Management Limited Liability Corp stated it has 2.5% of its portfolio in Johnson & Johnson (NYSE:JNJ). Lawson Kroeker Management Incorporated Ne has 4.08% invested in Johnson & Johnson (NYSE:JNJ). Etrade Cap Mngmt Lc stated it has 0.29% of its portfolio in Johnson & Johnson (NYSE:JNJ). Violich Management reported 4.04% in Johnson & Johnson (NYSE:JNJ). Benjamin F Edwards And Inc has 1.11% invested in Johnson & Johnson (NYSE:JNJ) for 75,968 shares. Alta Lc stated it has 1,784 shares or 0.02% of all its holdings. Benedict Fincl Inc reported 52,598 shares. Wedgewood Investors Inc Pa has 1.36% invested in Johnson & Johnson (NYSE:JNJ) for 11,948 shares. The Massachusetts-based Colony Grp Ltd has invested 0.29% in Johnson & Johnson (NYSE:JNJ). Moreover, Hsbc Holdings Pcl has 1.23% invested in Johnson & Johnson (NYSE:JNJ). Hyman Charles D stated it has 4.25% of its portfolio in Johnson & Johnson (NYSE:JNJ). Td Asset Mgmt stated it has 3.11M shares or 0.63% of all its holdings. Manufacturers Life Insurance Com The holds 0.96% or 6.38M shares in its portfolio. Cannell Peter B & holds 204,698 shares.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 100 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by BMO Capital Markets on Friday, June 2. Leerink Swann maintained the stock with “Buy” rating in Wednesday, April 18 report. The firm has “Sell” rating given on Tuesday, January 23 by BTIG Research. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, April 10. The firm has “Hold” rating given on Thursday, August 4 by Jefferies. The firm has “Buy” rating by UBS given on Thursday, August 31. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 18. Jefferies has “Buy” rating and $161.0 target. The stock has “Buy” rating by BMO Capital Markets on Monday, July 10. Cowen & Co maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, August 24. Cowen & Co has “Buy” rating and $147.0 target. As per Wednesday, October 7, the company rating was maintained by RBC Capital Markets.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: 247Wallst.com which released: “Johnson & Johnson Commits to Yet Another Dividend Hike” on April 26, 2018, also Seekingalpha.com with their article: “Johnson & Johnson (JNJ) Consumer and Medical Devices Business Review – Brokers Conference Transcript” published on May 17, 2018, Seekingalpha.com published: “Johnson & Johnson: Waiting On The Wave” on May 11, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Livetradingnews.com and their article: “Johnson & Johnson (NYSE:JNJ) Stock Oversold” published on May 03, 2018 as well as Forbes.com‘s news article titled: “How Sensitive Is Johnson & Johnson To Its R&D Expense Change?” with publication date: May 17, 2018.

Since February 15, 2018, it had 0 insider buys, and 1 insider sale for $20.17 million activity.

Alpine Partners Vi Llc, which manages about $439.93M US Long portfolio, decreased its stake in Santander Consumer Usa Hdg I (NYSE:SC) by 31,867 shares to 18,133 shares, valued at $338,000 in 2017Q4, according to the filing. It also reduced its holding in Amazon Com Inc (NASDAQ:AMZN) by 3,053 shares in the quarter, leaving it with 351 shares, and cut its stake in Entercom Communications Corp (NYSE:ETM).

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.